ICU Medical (ICUI)
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
Research Workspace
Put ICUI beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Health Care Supplies: fringe margins under pressure (0q confirmed)
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisRevenue is contracting — down about 9% over the past year.
View GrowthMiddle-of-the-pack quality for its industry.
View QualityManagement screens strong on earnings delivery, margins, the balance sheet, market reaction to earnings.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskICU Medical's strong organic growth and improved net income support a positive outlook. Revenue grew 1% year over year, and the latest quarter beat expectations by 59%. It trades at 21× P/E versus a peer median of 23×, indicating it looks expensive on this basis. The next-quarter miss probability is 19%, which suggests a risk of disappointing guidance. Peer multiples imply a price about 3% below where it trades. Our read remains intact.
Trailing returns as of 2026-09-04. ICUI is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 8 analysts currently covering ICUI (as of Sep 2026).
Based on 4 Wall Street analysts offering 12-month price targets for ICUI in the last 4 months.
Continue this research
Compare ICUI with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| ICUI Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 12 valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Health Care Supplies — fair value, gap to price, and forward P/E.
Compare the value case
Put ICUI next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Increase cash from operations
Upgrade indicates improved financial health and cash flow potential.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-09-04. EPS is implied from price ÷ P/E. Not investment advice.
Current $167.58
The last 12 months of price, then the range of analyst 12-month targets from today’s $167.58.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Above average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.

Advances: Enhance gross profit
Margin expansion enhances gross profit significantly.
Advances: Improve net income
Strong organic growth supports improved net income objective.

Advances: Enhance gross profit
Increased EPS outlook supports gross profit enhancement.

Advances: Improve net income
Earnings beat indicates improved net income performance.

Advances: Improve net income
Strong Q2 results indicate improved net income performance.
Advances: Increase cash from operations
Expansion enhances cash flow and operational capacity.
Advances: Increase cash from operations
Upgrade supports increased cash from operations outlook.